PMV PHARMACEUTICALS, INC. Payments to Acquire Productive Assets
PMV PHARMACEUTICALS, INC. (PMVP) reported Payments to Acquire Productive Assets of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-09.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2026-03-06
- PMV PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2024-03-31 was $6.00K, a 97.99% decline year-over-year.
- PMV PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2023-03-31 was $298.00K, a 79.25% decline year-over-year.
- PMV PHARMACEUTICALS, INC. payments to acquire productive assets for the quarter ending 2022-12-31 was -$574.00K.
- PMV PHARMACEUTICALS, INC. payments to acquire productive assets for fiscal 2023 was $6.00K, a 96.94% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. payments to acquire productive assets for fiscal 2022 was $196.00K, a 85.91% decline from fiscal 2021.
- PMV PHARMACEUTICALS, INC. payments to acquire productive assets for fiscal 2021 was $1.39M.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | |||
| 2024-03-31 | $6.00K 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $6.00K 10-K · filed 2026-03-06 | |||
| 2023-03-31 | $298.00K 10-Q · filed 2024-05-09 | -$276.00K derived: sum of 2 quarters · filed 2025-03-03 | -$1.01M derived: sum of 3 quarters · filed 2025-03-03 | -$942.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$574.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.30M derived: sum of 2 quarters · filed 2025-03-03 | -$1.24M derived: sum of 3 quarters · filed 2025-03-03 | $196.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | -$731.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$666.00K derived: sum of 2 quarters · filed 2023-11-09 | $770.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.50M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $1.44M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $1.39M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |